Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases

Language
English

File attachments: 
AttachmentSize

Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis- Report of Experience in Three Cases.pdf248.18 KB

7
Average: 7 (1 vote)

• Neuroborreliosis
• Chronic Lyme disease
• Post-treatment Lyme disease syndrome (PTLDS)
• Babesia

• Case Report

• Off-Label Pharmacotherapy

• Disulfiram

antibiotics

Article
Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases
Kenneth B. Liegner 1,2,3
1 2 3
Received: 28 March 2019; Accepted: 25 May 2019; Published: 30 May 2019

592 Route 22—Suite 1B, Pawling, NY 12564, USA Northwell System, Northern Westchester Hospital, Mount Kisco, NY 10549, USA Health Quest System, Sharon Hospital, Sharon, CT 06069, USA; kbliegnermd@optonline.net; Tel.: +1-845-493-0274; Fax: +1-845-493-0279

Abstract: Three patients, each of whom had required intensive open-ended antimicrobial therapy for control of the symptoms of chronic relapsing neurological Lyme disease and relapsing babesiosis, were able to discontinue treatment and remain clinically well for periods of observation of 6–23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram.
Keywords: Chronic Lyme disease; neuroborreliosis; Post-treatment Lyme disease syndrome (PTLDS); relapsing babesiosis; persistent infection; antibiotic treatment failure; disulfiram